Glucagon-Like Peptide-1 Protects Against Atrial Fibrillation and Atrial Remodeling in Type 2 Diabetic Mice

Loryn J Bohne; Hailey J Jansen; Tristan W Dorey; Irene M Daniel; K Lockhart Jamieson; Darrell D Belke; Megan D McRae; Robert A Rose

doi:10.1016/j.jacbts.2023.01.005

Glucagon-Like Peptide-1 Protects Against Atrial Fibrillation and Atrial Remodeling in Type 2 Diabetic Mice

JACC Basic Transl Sci. 2023 Mar 15;8(8):922-936. doi: 10.1016/j.jacbts.2023.01.005. eCollection 2023 Aug.

Authors

Loryn J Bohne¹, Hailey J Jansen¹, Tristan W Dorey¹, Irene M Daniel¹, K Lockhart Jamieson¹, Darrell D Belke¹, Megan D McRae¹, Robert A Rose¹

Affiliation

¹ Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Department of Cardiac Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; and the Department of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Abstract

Atrial fibrillation (AF) is highly prevalent in type 2 diabetes where it increases morbidity and mortality. Glucagon-like peptide (GLP)-1 receptor agonists are used in the treatment of type 2 diabetes (T2DM), but their effects on AF in T2DM are poorly understood. The present study demonstrates type 2 diabetic db/db mice are highly susceptible to AF in association with atrial electrical and structural remodeling. GLP-1, as well as the long-acting GLP-1 analogue liraglutide, reduced AF and prevented atrial remodeling in db/db mice. These data suggest that GLP-1 and related analogues could protect against AF in patients with T2DM.

Keywords: arrhythmia; electrophysiology; fibrosis. incretin; ion channels.